Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AHA
AHA
Intellia’s gene editing therapy shows early potential in rare heart condition
Clinical Trials Arena
Mon, 11/18/24 - 11:30 am
Intellia
gene editing
NTLA-2001
AHA
ATTR-CM
Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Clinical Trials Arena
Fri, 11/17/23 - 11:29 am
Lexicon Pharmaceuticals
Inpefa
clinical trials
heart failure
AHA
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
Fierce Pharma
Tue, 11/14/23 - 09:56 pm
JNJ
Bayer
Xarelto
blood thinners
AHA
peripheral artery disease
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
Pharmaphorum
Mon, 11/13/23 - 10:03 am
Eli Lilly
AHA
siRNA
lipoprotein(a)
cardiovascular disease
lepodisiran
AHA 2020 – sotagliflozin wins come too late for Lexicon
EP Vantage
Tue, 11/17/20 - 10:45 am
Lexicon Pharmaceuticals
sotagliflozin
AHA
heart failure
chronic kidney disease
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
Fierce Pharma
Mon, 11/16/20 - 10:33 pm
Amarin
Vascepa
AHA
AHA 2020 – look out for the omecamtiv fault lines
EP Vantage
Mon, 11/16/20 - 10:13 am
AHA
Omecamtiv Mecarbil
Amgen
Cytokinetics
heart failure
AHA to HHS: Stop drugmakers' 'abusive tactics' over 340B discounts
Beckers Hospital Review
Fri, 09/11/20 - 10:49 am
HHS
AHA
Alex Azar
340B
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
Mon, 11/18/19 - 10:29 am
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
AHA: Caladrius single injection helps heart disease that hits women the hardest
Fierce Biotech
Mon, 11/18/19 - 10:09 am
Caladrius Biosciences
Women's Health
heart disease
AHA
CLBS16
Syndrome X
AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
Fierce Pharma
Mon, 11/18/19 - 10:06 am
AHA
Amgen
Repatha
PCSK9 inhibitor
heart attacks
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
Fierce Pharma
Mon, 11/18/19 - 09:54 am
Amarin
Vascepa
AHA
FDA
aterial plaque
AHA: MedCo's PCSK9 rival inclisiran hits LDL
Fierce Biotech
Mon, 11/18/19 - 09:53 am
AHA
The Medicines Company
inclisiran
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
Sun, 11/17/19 - 08:47 pm
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata
Fierce Pharma
Sun, 11/17/19 - 08:38 pm
Novartis
AHA
Entresto
AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on
Fierce Pharma
Sun, 11/17/19 - 08:35 pm
AstraZeneca
Brilinta
Farxiga
AHA
AHA: UnitedHealth report on steep specialty drug costs lets drugmakers off the hook
Beckers Hospital Review
Wed, 09/11/19 - 10:24 am
AHA
UnitedHealth
specialty drugs
drug pricing
Boston Scientific Stands Behind Its Stents in Wake of JAHA Article and FDA Investigation
BioSpace
Tue, 01/22/19 - 11:46 am
devices
Boston Scientific
FDA
AHA
paclitaxel
stents
Newly vocal union targets Big Pharma's payments to AHA and its leaders
Fierce Pharma
Sat, 09/19/15 - 03:29 pm
unions
Big Pharma
AHA
CME
Crestor shines, Vitamin D intrigues at AHA confab
Fierce Pharma
Wed, 11/18/09 - 12:14 pm
AHA
Crestor
AstraZeneca